This software bot accelerates and streamlines the scheduling of hundreds of thousands of patient appointments to receive the two-shot vaccine for COVID-19.
Clalit Health Services, the largest healthcare maintenance organization in Israel, has already used the Kryon V-Bot to schedule more than 100,000 vaccine appointments per day.
Israel leads the world in COVID vaccinations and having already vaccinated 30% of its eight m citizens.
The logistical problems facing healthcare organizations attempting a controlled COVID-19 vaccine roll-out are astounding.
Many hospitals, healthcare providers and HMOs receive vaccines with little notice, placing enormous stress on support staff to schedule last minute appointments and use every available dose.
By automating scheduling based on eligibility criteria, the burden is lifted allowing them to focus on areas that require a human touch, like patient care and service.
Kryon is offering the V-Bot to all healthcare providers to expedite the required double-appointment setting. The purchase of Kryon V-Bot includes an unlimited amount of software bots to assist in the mass scheduling.
Further, Kryon will also customize the automation workflow of an organization's patient scheduling process based on an individual organization's structure and needs.
Kryon is in enterprise automation, offering the only platform on the market which encompasses both Process Discovery technology and Robotic Process Automation (RPA).
The Kryon Full-Cycle Automation solution maximizes ROI by 352% according to Forrester Research and cuts RPA implementation time by up to 80%.
Powered by proprietary AI technology, Kryon Process Discovery automatically generates a comprehensive picture of business processes, evaluates them, and recommends which ones to automate.
Kryon offers desktop-based attended RPA, virtual-machine-based unattended RPA, or a hybrid combination of both. The company's award-winning suite is used by enterprises worldwide, including AIG, Allianz, Deutsche Telekom, EY, Ferring Pharmaceuticals, HP, Microsoft, Santander Bank, Singtel, Verizon, and Wyndham Hotel Group.
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
BioDlink convenes peer advisory event on innovation and collaboration strategies
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China
Neurizon enters global license agreement with Elanco to commercialise NUZ-001